Kit for rapidly detecting avian leukosis J subtype based on CRISPR / Cas13a system
Through the rapid detection method based on the CRISPR/Cas13a system, the early diagnosis problem of ALV-J detection is solved using specific crRNA and RAA amplification technology, and high sensitivity and specific detection are achieved. It is suitable for remote areas and reduces detection costs. and equipment requirements.
Patent Information
- Application Number
- CN202411350812.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-26
- Publication Date
- 2024-11-22
AI Technical Summary
The existing avian leukemia virus J subtype (ALV-J) detection methods have problems such as long detection cycle, high cost, complex operation and difficult to deploy in remote areas. In particular, the detection methods of specific antibody immunohistochemistry are cumbersome and difficult to operate. It is difficult to make early diagnosis quickly and accurately.
Using a rapid detection method based on the CRISPR/Cas13a system, the gp85 gene in the ALV-J genome-wide env sequence was identified by designing specific crRNA, combining RAA amplification and T7 transcriptase, and using fluorescent reporter genes and lateral chromatography test papers The bar enables fast, sensitive and economical testing.
Fast, high sensitivity and specific detection of ALV-J is achieved, and can detect ALV-J at viral nucleic acid concentrations as low as 5.4×100 copies/ul, reducing detection costs and not requiring expensive experimental equipment and Special laboratory environment, suitable for remote areas with limited resources.
Smart Images

Figure CN118996012A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of detection, and in particular to a kit for rapidly detecting avian leukemia J subtype based on a CRISPR / Cas13a system. Background Art
[0002] ALV belongs to the Retroviridae family and the genus A-retrovirus. It is characterized by sporadic disease (morbidity rate is 3%-25%). ALV was first discovered by Rous in the UK in 1911. Since then, ALV has been detected in chicken farms around the world. ALV infection can cause immunosuppression in chickens, inhibit their growth, and induce tumors leading to death. The mortality rate is 1%-2%, and some chicken farms with poor environment can even reach 20%. Despite more than a century of research, there is still no vaccine that can protect chickens from ALV infection.
[0003] According to the different host ranges, the interaction between different strains and the antigenic structure of the viral envelope glycoprotein, ALV is divided into 11 subgroups (AK), among which the E subgroup belongs to endogenous ALV, which is not pathogenic or has very low pathogenicity. In 1991, Payne discovered and isolated a new subgroup of avian leukosis virus and named it J subgroup. J subgroup can induce various types of tumors in chickens, mainly myeloblastic tumors. Unlike other subgroups of avian leukosis virus (ALV), ALV-J is much more contagious and pathogenic than the classic A, B, C, and D subgroups of ALV. In the mid-1990s, it had spread to almost all white-feathered broiler flocks in all countries around the world. It has caused great losses to the global poultry industry. ALV-J is transmitted horizontally and vertically. Once the J subtype of avian leukosis virus (ALV-J) appears in the breeder farm and is not purified in time, all parent and commercial generation chickens may be infected. This situation can cause the virus to spread rapidly throughout the flock, causing serious economic losses and public health risks to the breeding industry. Therefore, timely detection and purification of ALV-J is crucial to protecting the health of the flock and maintaining production benefits.
[0004] Therefore, given that diseases caused by ALV-J infection usually break out in local breeder farms and start and spread in super-large chicken farms, early diagnosis of ALV-J is particularly important in prevention and control work. Existing methods for determining ALV-J infection include polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), indirect fluorescent antibody reaction (IFA), virus isolation detection, specific antibody immunohistochemistry technology to detect ALV-J in diseased materials, nucleic acid technology to detect pathogenic exogenous ALV-J, and RT-PCR and nucleic acid probe molecular hybridization technology to detect ALV-J specific nucleic acid. Among them, the specific antibody immunohistochemistry method for detecting ALV-J in diseased materials is relatively cumbersome and difficult to operate, and only limited specimens can be selected for use. The virus isolation method is recognized as the international gold standard for detecting viruses. This method mainly inoculates the collected plasma into cells, and after 7 to 9 days of culture, uses the ALV-J ELISA antigen kit for detection. However, this method has a long detection cycle, high cost, and requires sophisticated instruments and skilled operating technicians, making it difficult to deploy in places far away from farms. Therefore, developing a virus detection method with high sensitivity and specificity, rapid detection, and simpler operation is crucial to promote the detection of ALV-J in remote areas.
[0005] CRISPR stands for Clustered regularly interspaced short palindromic repeats. The CRISPR / Cas system is a self-protection mechanism of archaea, called the adaptive immune system, which was first discovered in 1987. CRISPR systems are divided into two categories due to their different components and mechanisms of action: one type of system consists of multi-protein complex effectors, and the other type of system consists of a single effector protein. The first type of system includes types I, III, and IV, and the second type of system includes types II, V, and VI. So far, at least 26 subtypes have been discovered. And different types and subtypes are expanding rapidly. Two type II RNA-guided nucleases have been used as biosensors, namely Cas12a and Cas13a, which target single-stranded or double-stranded DNA and single-stranded RNA, respectively. Cas13 forms a complex with crRNA to recognize the targeted ssRNA, thereby activating the HPEN domain in the Cas13a protein, which can cut all ssRNAs in the environment.
[0006] Due to the specific cutting function and convenience of CRISPR-Cas13a detection, the system has been applied to the detection of various diseases and some biomarkers. Zheng Feng et al. used the signal transduction process of CRISPR-Cas13a to develop a SHERLOCK system for target nucleic acid detection, which is used to specifically detect Zika virus. crRNA determines the specificity of CRISPR detection. Parinaz Fozouni et al. designed crRNA that combines multiple regions of SARS-CoV-13 viral RNA to improve the sensitivity of CRISPR detection; in addition, the use of lateral chromatography also realized the detection of NiV virus based on the CRISPR / Cas13a system and the serum detection of poultry adenovirus. In order to solve the background influence in the RNA amplification process, Parinaz Fozouni et al. developed a CRISPR / Cas13a detection method that does not require amplification. The test results can be read within 30 minutes using a mobile phone microscope, which is more convenient and quick.
[0007] Compared with traditional PCR and qPCR molecular virus diagnosis methods, the CRISPR method shows advantages in sensitivity, ease of operation and economy.
[0008] Given the successful application of the CRISPR-Cas13a system in the detection of the above-mentioned multiple viruses, it is speculated that the system can also be effectively used to detect avian leukosis virus subtype J (ALV-J). By designing specific crRNA, the CRISPR-Cas13a system can recognize and cut the probe RNA, providing a fast, sensitive and economical detection method. This not only helps to timely detect and control the spread of ALV-J, but also significantly reduces the cost of detection, especially for remote areas with limited resources.
[0009] Therefore, it is urgent to develop a two-tube detection method for the detection of ALV-J using the CRISPR system. Summary of the invention
[0010] In view of this, one of the objects of the present invention is to provide a kit for rapid detection of avian leukosis J subtype based on CRISPR / Cas13a system. The present invention designs crRNA using the gp85 gene in the ALV-J whole genome env sequence to maximize its specificity in all ALV-J isolates or variants; the second object of the present invention is to provide the use of the kit in detecting avian leukosis J subtype in vitro.
[0011] In order to achieve the above object, the present invention provides the following technical solutions:
[0012] 1. A kit for rapid detection of avian leukosis J subtype based on the CRISPR / Cas13a system, the kit comprising a RAA amplification reagent and a CRISPR-Cas13a detection reagent for T7 transcriptase;
[0013] The RAA amplification reagent contains a primer pair as shown in SEQ ID NO.1 and SEQ ID NO.2, SEQ ID NO.4 and SEQ ID NO.5, or SEQ ID NO.8 and SEQ ID NO.9;
[0014] The CRISPR-Cas13a detection reagent of the T7 transcriptase includes T7 transcriptase, Cas13a, a fluorescent reporter gene, and a crRNA primer; the sequence of the fluorescent reporter gene is shown in SEQ ID NO.23; the crRNA primer is as described in SEQ ID NO.13 and SEQ ID NO.14, SEQ ID NO.17 and SEQ ID NO.18, or SEQ ID NO.21 and SEQ ID NO.22.
[0015] Preferably, the RAA amplification reagent further comprises Reactive Powder, RNA sample, A buffer and B buffer.
[0016] Preferably, the CRISPR-Cas13a detection reagent of the T7 transcriptase also includes Buffer, RNA inhibitor, rNTP, HEPES, MgCl2 and RNA Targrt, and the RNA Targrt is an RAA amplification product.
[0017] Preferably, the kit further comprises a lateral flow test strip, the test strip comprising a binding pad area, a detection area and a control area, the binding pad area is fixed with a 6-FAM-UUUUUUUUUUUUUU-C6 Biotin RNA probe, the detection area comprises a T line, the T line is fixed with a capture molecule, the capture molecule can specifically bind to the C6 Biotin on the probe, after the target RNA-probe complex is captured, the detection area of the test strip will form a fluorescent line or a color line; the control area comprises a C line, and the FAM antibody is fixed on the C line.
[0018] Preferably, the capture molecule of the present invention is streptavidin or avidin.
[0019] 3. Application of the kit in detecting J subtype of avian leukemia in vitro.
[0020] The beneficial effects of the present invention are as follows: the present invention provides a kit for rapid detection of avian leukosis J subtype based on the CRISPR / Cas13a system. The method is a method for detecting ALV-J based on the CRISPR / Cas13a system and RAA amplification. The oligonucleotide probe is designed as a substrate for CRISPR / Cas13a trans-cleavage and generates a detectable signal. The method amplifies the detection signal twice by RAA amplification and T7 transcription, which can greatly improve the sensitivity of the detection. The minimum limit of this new detection is 5.4*10 0 In addition, the detection method has good specificity and can clearly distinguish other avian viruses. This method does not require expensive experimental equipment and special laboratory environment, and is fast and efficient. This method is of great significance for the biological research and on-site detection of ALV-J. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to make the purpose, technical solution and beneficial effects of the present invention clearer, the present invention provides the following drawings for illustration:
[0022] Figure 1 It is the RAA amplification gel electrophoresis detection (M: Maker; 1-5: the amplification results of primers 1-5 respectively);
[0023] Figure 2 The purified LwaCas13 protein was measured by SDS-PAGE (1, 2, 3, 4, 5 and 6 represent different lanes and different proteins, respectively);
[0024] Figure 3 It is the principle of two-step RAA-CEISPR / Cas13a detection technology;
[0025] Figure 4 To continuously monitor the fluorescence results for 80 minutes;
[0026] Figure 5 Fluorescence intensity for optimizing reaction time and temperature (A: time; B: temperature);
[0027] Figure 6 To optimize the crRNA concentration, Cas13a concentration and fluorescence intensity of RAA amplification products (A: crRNA concentration; B: Cas13a concentration; C: RAA amplification products);
[0028] Figure 7 It is the result of lateral flow test paper test;
[0029] Figure 8 is the sensitivity of RAA-CRISPR / Cas13a to ALV-J;
[0030] Fig. 9It is the sensitivity of lateral flow test strip detection;
[0031] Fig.10 It is the specific result of CRISPR / Cas13a detection system;
[0032] Fig.11 The clinical samples were tested by fluorescence and electrophoresis respectively (A: amplification curve; B: electrophoresis test results; C: fluorescence test results). DETAILED DESCRIPTION
[0033] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0034] Example 1, design of RAA primers and crRNA
[0035] Since the gp85 sequence of the envelope glycoprotein is the basis for the identification of ALV subgroups, in order to improve the specificity of the RAA results, the gp85 sequences of ALV-J, A, B, and K were downloaded from the National Center for Biotechnology Information NCBI (https: / / www.ncbi.nlm.nih.gov / ), and the DNAstar (version 11.1.0) software was used for comparison to screen out the conservative sequence of ALV-J. The RAA primers containing the T7 promoter were designed by Primer (https: / / blast.ncbi.nlm.nih.gov / ). The primers were synthesized by Wuhan Tianyi Huayu Gene Technology Co., Ltd. (Wuhan, China). The specific sequences are shown in Table 1:
[0036] Table 1. RAA primer sequences
[0037]
[0038] The designed primers were used for amplification, and the amplified products were detected by 2.5% agarose gel electrophoresis. Figure 1 The results showed that the amplified product (116 bp) after RAA amplification and the brightness of the RPA product of primers 1, 3 and 5 under the gel imager were higher than other primers, indicating that primers 1, 3 and 5 were more suitable for detection.
[0039] The crRNA for detection was designed in the CHOPCHOP website based on the aligned ALV-J conserved sequence. The crRNA was generated from the DNA template by in vitro transcription (IVT), and the T7 polymerase promoter sequence was attached to the 5' end of the template. The DNA template of the crRNA was synthesized by Wuhan Tianyi Huayu Gene Technology Co., Ltd. The DNA template of the crRNA is shown in Table 2.
[0040] Table 2. DNA templates of crRNA
[0041]
[0042] Example 2, preparation of crRNA and RNA reporter
[0043] To generate double-stranded DNA, the crRNA oligonucleotides containing T7 promoter in Table 2 were annealed into dsDNA using DNA oligonucleotide annealing buffer (TAKARA, China) and HiScribe T7 fast high-yield RNA synthesis kit (New England Biolabs (NEB), Ipswich, MA, USA). The synthesized dsDNA was purified using a DNA purification kit (TAKARA, China), and the transcribed crRNA was purified using an RNA purification kit (Shanghai, China). The RNA concentration was determined using NanoDrop One, and the purified crRNA was then kept at -80 ° C until use.
[0044] The fluorescent reporter RNA labeled with FAM and BHQ1 at both ends was synthesized by Guangzhou Editgene Co., Ltd, China. The reporter RNA labeled with FAM and Biotin at both ends was synthesized by Wuhan Tianyi Huayu Gene Technology Co., Ltd. The specific sequence is shown in Table 3.
[0045] Table 3. Primes for ssRNA Reporter
[0046]
[0047] Example 3. Purification and large-scale expression of LwaCas13 protein
[0048] The LwaCas13 protein modified with the His tag and the SUMO tag needs to undergo a series of purification and de-labeling. The plasmid pC013-Twinstrep-SUMO-huLwCas13a (Miaoling Biotechnology, China) containing the inserted LwaCas13a gene is transformed into BL21 (DE3) Escherichia coli, and 1 mL / L 0.5 M IPTG is added for 14 h of low-temperature induction expression at 16 ° C. The induced bacterial solution is crushed under an ultrasonic crusher, and the supernatant containing LwaCas13 is collected by centrifugation at 4 ° C and 8000 rpm for 30 minutes. The supernatant is filtered using a 22 μm filter, and then the LwaCas13a protein is purified using a NI-NTA pre-loaded gravity column. The impurities are eluted using an imidazole gradient of 20 mM, 50 mM, and 80 mM. The Cas13 protein bound to the NI column is eluted using 500 mM imidazole, and the solution containing the LwaCas13 protein is collected. 1.5% SUMO enzyme was used to remove the SUMO tag overnight at 4°C. The collected eluate was concentrated using an ultrafiltration tube (Millipore, Germany), and finally the purified LwaCas13 protein was determined by SDS-PAGE and Coomassie Brilliant Blue staining. The results are as follows Figure 2 As shown. The results showed that highly pure and active Cas13a protein was successfully obtained. The BCA kit (Biyuntian) was used for quantification and stored at -80°C for future use.
[0049] Example 4. Preparation of viruses
[0050] Liver, plasma and cloaca samples were collected from poultry individuals showing symptoms of avian leukosis at a chicken farm in Chongqing. Virus isolation and identification results provided by the Avian Leukosis Laboratory of the College of Animal Science and Technology of Southwest University showed that positive samples contained ALV-J virus. Following the manufacturer's instructions of the Simple Viral DNA / RNA Kit, viral RNA was successfully extracted. Subsequently, the RNA was reverse transcribed into cDNA for subsequent experiments. Meanwhile, the DNA samples were properly stored at -20°C until further use.
[0051] Example 5. Construction of standard plasmid
[0052] In order to explore the sensitivity of the system in detecting viruses, the gp85 sequence of the reference ALV-J isolate was used. The specific sequence is shown in SEQ ID NO.23:
[0053] ggagttcatctgttgcaacaaccagggaacgtatgggtcacctgggcaaataagacgggccaaacagatttttgccttagtctacagtcggctac
[0054] ctctcccttccgcacctgtttggtgggtttgccgagttaccaattggaggagtttagaggatatacggtcaactacactggatgtaaaaatgataca
[0055] gatgcggccacacagacggcgtgtctgattcaatcattaaatcgtaccctcccttgggacccccaagaattggatattttagggtcccagatgatc
[0056] aagaacggaacaacacgtacgtgtgttacctttggttcggtgtgctataaagagaacaatcgcagtagagtctgtcacaattttgatgggaatttta
[0057] atgggactggtggggcagaagcagaattgcgtgacttcatagcaaaatggaaaagtgatgaccttcttataagaccctatgtcaaccaatcatgg
[0058] acgatggtaagtccaataaacgtagagagtttttcaataagtcgtagatattgtggattcaccagtaacgagactcgttactatagaggggacctttc
[0059] taattggtgtggttcaaaaaggggaaaatggtcagcggggtacagcaacgggacaaaatgttccagcaacacgacgggttgcggtggtaattg
[0060] cacgacggaatggaattattatgcatatgggtttaccttcgggaaacagccagaggtgttgtggaacaatgggactgctaaggcactcccccca
[0061] ggtattttcttgatttgtggggacagggcttggcaaggcatcccgcgtaatgccttgggagggccctgttatctaggacaattgactatgctctctcc
[0062] taactttaccacctggataacatatgggccgaacattacgggtcaccgccgtagcaggcgc
[0063] The gp85 sequence was synthesized by Wuhan Jinkairui Company and then cloned into the PUC-57 vector to obtain gp85-PUC-57.
[0064] Example 6: Two-step RAA-CRISPR / Cas13a detection
[0065] This study used a two-step RAA-CEISPR / Cas13a detection technique, the principle is as follows Figure 3 As shown. The technology includes a RAA amplification step and a CRISPR-Cas13a detection system containing T7 transcriptase. According to the instructions of the kit manufacturer (the reagents were purchased from Hangzhou Zhongce Biotechnology Co., Ltd. Room Temperature RAA Amplification Kit), first prepare a premix on ice, which contains 2μl (10μM) of forward primer (RAA-Prime-3F), 2μl (10μM) of reverse primer (RAA-Prime-3R), 1μL of Reactive Powder, 5μL of RNA sample, 25μL of A buffer, and 2.5μL of B buffer, and then quickly vortex to mix. Finally, react at 42°C in a metal bath for 30 minutes.
[0066] For CRISPR-Cas13a detection, T7 transcription is essential. 50nM LwaCas13a 0.2μl, Buffer 4μL, 500nM crRNA 1μL, 2μM ssRNA Reporter 1.25μL, 40U RNA Inhibitor 1μL, 1μM RNA Target 0.6μL, rNTP mixture / 25mM 0.8μL, HEPES / 1M 0.4, MgCl2 / 1M 0.18μL, T7
[0067] Transcriptases / 5U 0.5μL, H2O 10.07μL total volume 20μL. The crRNA was added last to activate the activity of Cas13a protein. To monitor the reaction, the mixture was incubated at 37°C and the fluorescence value was recorded every 30 seconds for 80 minutes to collect data. The results are shown in Figure 4As shown. The results showed that when none of the following components were present in the detection system: Cas13a protein, crRNA or RAA amplification product, the fluorescence signal remained unchanged. When Cas13a protein, crRNA and RPA product were present at the same time, the fluorescence signal increased significantly. The results showed that only in the complete system can the target RNA of ALV-J activate the Cas13a / crRNA trans-cleavage system.
[0068] Since Cas13a protein participates in the detection reaction as an enzyme, the ability of the detection system is closely related to other parameters such as reaction time, temperature, enzyme concentration, target RNA, etc. Therefore, in order to achieve the best detection effect, we optimized some reaction conditions. Therefore, the reaction time of the CRISPR-Cas13a system was set to 10min, 20min, 30min, 50min, 60min and 80min respectively; the temperature was 25℃, 28℃, 33℃ and 37℃; the results are as follows Figure 5 As shown. The results show that the fluorescence intensity reaches the maximum value at 37°C and 30min. In addition, the concentration of crRNA, Cas13a and RAA amplification product were also optimized by fluorescence intensity. The results are shown in Figure 6 The results showed that strong fluorescence could be obtained when the crRNA concentration was higher than 400nM and the Cas13a concentration was higher than 0.1nM, and the fluorescence intensity of the RAA amplification product was the highest when the concentration was 1.2μL.
[0069] Construct a lateral flow test strip to verify the CRISPR-Cas13a detection system for ALV-J. The specific method is as follows:
[0070] (1) Preparation of sample mixture:
[0071] The sample to be tested was mixed with other reagents required for the reaction (such as RAA amplification reagent and CRISPR-Cas13a system), and DEPC water was finally added to a total volume of 50 μL.
[0072] Preparation of lateral flow test strips: Immobilize 6-FAM-UUUUUUUUUUUUUU-C6Biotin RNA probe on the conjugate pad area of the test strip. The polyuridylic acid portion (UUUUUUUUUUUUUU) of the probe will complementarily pair with the target RNA in the sample to form an RNA-probe complex.
[0073] The detection area includes a T line, which is fixed with capture molecules such as streptavidin or avidin, which can specifically bind to the C6 Biotin (biotin label) on the probe; when the target RNA-probe complex is captured, a fluorescent line or color line will be formed in the detection area of the test strip, and the strength of this signal is related to the concentration of the target RNA. The probe that has not bound to the target RNA continues to move forward and enters the control area. In the control area, another binding molecule, such as anti-6-FAM antibody or other capture molecules, is often fixed, which will bind to the 6-FAM part on the probe to form a C line.
[0074] During the test, leave the test strip still and make sure its lower section is always immersed in the mixed solution for 10 minutes. Observe the result on the test strip after 10 minutes. The result after 10 minutes is invalid.
[0075] Result determination: A positive result is determined only when the C line (control line) and T line (test line) on the test strip show color at the same time.
[0076] If only the C line is colored but the T line is not, or if there is no color at all, it is considered a negative result.
[0077] Test results such as Figure 7 The results showed that the first test strip was positive, and the rest were negative.
[0078] Example 7. Sensitivity of CRISPR / Cas13a system in detecting ALV-J
[0079] The optimized experimental conditions were used to explore the minimum limit of the system in ALV-J detection. 9 The plasmid DNA copies / ul was diluted 10-fold with RNase-free water to generate a concentration gradient. The sensitivity of RAA-CRISPR / Cas13a to ALV-J was evaluated by this gradient. The results are shown in Figure 8 The results showed that as the ALV-J concentration increased, more ssRNA was available, so more Cas13a side branch cleavage was activated, resulting in a significant increase in fluorescence.
[0080] The concentrations were 10 9 , 10 8 , 10 7 , 10 6 , 10 5 , 10 4 , 10 3 , 10 2 , 10 1 , 10 0 The viral nucleic acid was tested by lateral flow test paper, and the results were as follows Fig. 9 The results showed that the CRISPR / Cas13a detection system can detect as low as 5.4×10 0 The copy number of viral nucleic acid was quantified. This demonstrated the superior performance of the CRISPR / Cas13a system in low-concentration virus detection.
[0081] Example 8. Specificity of CRISPR-Cas13a in detecting ALV-J
[0082] An excellent avian leukosis virus detection method is able to distinguish different avian viruses (NDV, IBD, MDV, AP). The specificity of the CRISPR / Cas13a detection system was evaluated using five different avian viruses. Fig.10 As shown in the figure, at the same starting concentration (100 nM), the change in fluorescence intensity of the same system was not significantly different from that of the blank control, and only ALV-J RNA produced a significant signal enhancement. These results show that the detection method has good specificity.
[0083] Example 9. Clinical sample detection of ALV-J using CRISPR-Cas13a
[0084] To further verify the applicability and accuracy of the CRISPR / Cas13a system in detecting target RNA in complex RNA extracts, we used Cas13a fluorescence detection to analyze viral RNA extracted from 300 blood samples collected from different chicken farms, using fluorescence and electrophoresis detection, respectively. Fig.11 As shown in the figure, there are significant differences between the experimental group and the control group. The experimental results show that this detection method can accurately identify the target RNA in complex RNA samples. Therefore, the detection method proposed in this experiment is the most powerful tool for detecting ALV-J in complex matrices.
[0085] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.
Claims
1. A kit for rapid detection of avian leukemia J subtype based on CRISPR / Cas13a system, characterized in that: The kit includes a RAA amplification reagent and a CRISPR-Cas13a detection reagent for T7 transcriptase; The RAA amplification reagent contains a primer pair as shown in SEQ ID NO.1 and SEQ ID NO.2, SEQ ID NO.4 and SEQ ID NO.5, or SEQ ID NO.8 and SEQ ID NO.9; The CRISPR-Cas13a detection reagent of the T7 transcriptase includes T7 transcriptase, Cas13a, a fluorescent reporter gene, and a crRNA primer; the sequence of the fluorescent reporter gene is shown in SEQ ID NO.23; the crRNA primer is as described in SEQ ID NO.13 and SEQ ID NO.14, SEQ ID NO.17 and SEQ ID NO.18, or SEQ ID NO.21 and SEQ ID NO.
22.
2. According to claim 1, a kit for rapid detection of avian leukemia J subtype based on the CRISPR / Cas13a system, characterized in that: The RAA amplification reagent also includes Reactive Powder, RNA sample, A buffer and B buffer.
3. According to claim 1, a kit for rapid detection of avian leukemia J subtype based on the CRISPR / Cas13a system, characterized in that: The CRISPR-Cas13a detection reagent of the T7 transcriptase also includes Buffer, RNA inhibitor, rNTP, HEPES, MgCl2 and RNA Targrt, and the RNA Targrt is an RAA amplification product.
4. According to claim 1, a kit for rapid detection of avian leukemia J subtype based on the CRISPR / Cas13a system, characterized in that: The kit also includes a lateral flow test strip, which includes a binding pad area, a detection area and a control area, wherein the binding pad area is fixed with a 6-FAM-UUUUUUUUUUUUUU-C6 Biotin RNA probe, the detection area includes a T line, the T line is fixed with a capture molecule, and the capture molecule can specifically bind to the C6 Biotin on the probe, and after the target RNA-probe complex is captured, the detection area of the test strip will form a fluorescent line or a color line; the control area includes a C line, and the FAM antibody is fixed on the C line.
5. According to claim 4, a kit for rapid detection of avian leukemia J subtype based on the CRISPR / Cas13a system, characterized in that: The capture molecule is streptavidin or avidin.
6. Use of the kit according to any one of claims 1 to 5 in detecting J subtype of avian leukosis in vitro.
Citation Information
Patent Citations
RPA primer for rapidly detecting avian leukosis virus J subgroup, probe, kit and detection method thereof
CN112575119A
RT-RAA fluorescence method detection primer pair, kit and detection method for J subtype avian leukosis virus gp85 gene
CN113930546A
Method for detecting avian leukosis virus based on RAA-CRISPR / cas13a-LFD
CN118240981A
Cited By
Detection system for simultaneously detecting circle virus poultry source type 1 and circle virus human source type 1 and application thereof
CN119662911A
